Clinical trial • Phase I/II • Respiratory
Morphine for Chronic obstructive pulmonary disease
Phase I/II trial of Morphine for Chronic obstructive pulmonary disease. 24 participants.
Overview
- Trial Therapeutic Area
- Respiratory
- Trial Disease
- Chronic obstructive pulmonary disease
- Trial Stage
- Phase I/II
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 09-08-2024
- First CTIS Authorization Date
- 07-10-2024
Trial design
Phase I/II trial across 1 site in France.
- Target Sample Size
- 24
Recruitment
- Planned Sample Size
- 24
- Recruitment Window Months
- 97
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 24
France
- Earliest CTIS Part Ii Submission Date
- 09-08-2024
- Latest Decision Or Authorization Date
- 07-10-2024
- Processing Time Days
- 59
- Number Of Sites
- 1
- Number Of Participants
- 24
Sites
- Site Name
- Centre Hospitalier Universitaire Grenoble Alpes
- Department Name
- Service des urgences adulte
- Principal Investigator Name
- Damien VIGLINO
- Principal Investigator Email
- Dviglino@chu-grenoble.fr
- Contact Person Name
- Damien VIGLINO
- Contact Person Email
- Dviglino@chu-grenoble.fr
- Number Of Participants
- 24
Sponsor
Primary sponsor
- Full Name
- Centre Hospitalier Universitaire Grenoble Alpes
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- Morphine
- Active Substance
- Morphine
- Modality
- Small molecule
Related trials
Other published trials that may interest you.
- AZITHROMYCIN DIHYDRATE for Chronic obstructive pulmonary disease
- DEPEMOKIMAB for Chronic obstructive pulmonary disease
- Clinical trial in Chronic Obstructive Pulmonary Disease
- 6-THIO-ALFA-D-GLUCOPYRANOSYL 6-THIO-ALFA-D-GLUCOPYRANOSIDE for Chronic obstructive pulmonary disease
- DUPILUMAB for Chronic obstructive pulmonary disease